Patents by Inventor Monika KRAMPERT

Monika KRAMPERT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220143071
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Application
    Filed: November 8, 2021
    Publication date: May 12, 2022
    Inventors: Markus HOSSBACH, Monika KRAMPERT, Hans-Lothar ARTH
  • Publication number: 20220090074
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: September 28, 2021
    Publication date: March 24, 2022
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • Patent number: 11213541
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: January 4, 2022
    Assignee: NEUROVISION PHARMA GMBH
    Inventors: Markus Hossbach, Monika Krampert, Hans-Lothar Arth
  • Patent number: 11162099
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: November 2, 2021
    Assignee: MINA THERAPEUTICS LIMITED
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • Publication number: 20210187007
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 24, 2021
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Saetrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Patent number: 10912790
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: February 9, 2021
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Publication number: 20200376020
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: April 21, 2016
    Publication date: December 3, 2020
    Applicant: MiNA THERAPEUTICS LIMITED
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Publication number: 20200255826
    Abstract: The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: September 7, 2018
    Publication date: August 13, 2020
    Inventors: Hans E. Huber, David Blakey, Jon Voutila, Monika Krampert, Markus Hossbach
  • Publication number: 20190314401
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Application
    Filed: June 14, 2019
    Publication date: October 17, 2019
    Inventors: MARKUS HOSSBACH, MONIKA KRAMPERT, HANS-LOTHAR ARTH
  • Patent number: 10363266
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: July 30, 2019
    Assignee: NeuroVision Pharma GmbH
    Inventors: Markus Hossbach, Monika Krampert, Hans-Lothar Arth
  • Publication number: 20170319614
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Application
    Filed: November 16, 2015
    Publication date: November 9, 2017
    Inventors: Markus HOSSBACH, Monika KRAMPERT, Hans-Lothar ARTH
  • Publication number: 20160138029
    Abstract: The present invention relates to antisense-oligonucleotides having a length of at least 10 nucleotides, wherein at least two of the nucleotides are LNAs, their use as inhibitors of TGF-R signaling, pharmaceutical compositions containing such antisense-oligonucleotides and the use for prophylaxis and treatment of neurological, neurodegenerative, fibrotic and hyperproliferative diseases.
    Type: Application
    Filed: November 16, 2015
    Publication date: May 19, 2016
    Inventors: Markus Hossbach, Monika Krampert
  • Publication number: 20150368642
    Abstract: The invention provides LNA therapeutics oligonucleotide carbohydrate conjugates with considerably enhanced potency, extended therapeutic index and reduced toxicity.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 24, 2015
    Inventors: Nanna ALBÆK, Henrik Frydenlund HANSEN, Susanne KAMMLER, Jacob RAVN, Henrik ØRUM, Mark TURNER, Monika KRAMPERT, Philipp HADWIGER, Søren OTTOSEN, Morten LINDOW